Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. Among authors: kwiatek j. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study.
Le TT, Emmanuel B, Katial R, Tran TN, Kwiatek JJ, Cohen DS, Daniel SR, Cao Y, Shih VH, Melcón MG, Devouassoux G, Pelaia G; RANS Study Investigators. Le TT, et al. Among authors: kwiatek jj. J Asthma Allergy. 2024 Apr 5;17:313-324. doi: 10.2147/JAA.S437190. eCollection 2024. J Asthma Allergy. 2024. PMID: 38595692 Free PMC article.
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data.
Stirnadel-Farrant HA, Xu X, Kwiatek J, Jain P, Meyers J, Candrilli S, Mines D, Datto CJ. Stirnadel-Farrant HA, et al. Among authors: kwiatek j. JAAD Int. 2023 Jun 9;13:117-125. doi: 10.1016/j.jdin.2023.04.014. eCollection 2023 Dec. JAAD Int. 2023. PMID: 37808963 Free PMC article.
Biologic Therapy in Rare Eosinophil-Associated Disorders: Remaining Questions and Translational Research Opportunities.
Khoury P, Roufosse F, Kuang FL, Ackerman SJ, Akuthota P, Bochner BS, Johansson MW, Mathur SK, Ogbogu PU, Spencer LA, Wechsler ME, Zimmermann N, Klion AD; International Eosinophil Society Clinical Research Interest Group. Khoury P, et al. J Leukoc Biol. 2024 Mar 8:qiae051. doi: 10.1093/jleuko/qiae051. Online ahead of print. J Leukoc Biol. 2024. PMID: 38457125
31 results